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Reprogramming triggers endogenous L1 and Alu
retrotransposition in human induced pluripotent
stem cells
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Human induced pluripotent stem cells (hiPSCs) are capable of unlimited proliferation and can
differentiate in vitro to generate derivatives of the three primary germ layers. Genetic and
epigenetic abnormalities have been reported by Wissing and colleagues to occur during
hiPSC derivation, including mobilization of engineered LINE-1 (L1) retrotransposons. However,
incidence and functional impact of endogenous retrotransposition in hiPSCs are yet to be
established. Here we apply retrotransposon capture sequencing to eight hiPSC lines and three
human embryonic stem cell (hESC) lines, revealing endogenous L1, Alu and SINE-VNTR-Alu
(SVA) mobilization during reprogramming and pluripotent stem cell cultivation. Surprisingly,
4/7 de novo L1 insertions are full length and 6/11 retrotransposition events occurred in
protein-coding genes expressed in pluripotent stem cells. We further demonstrate that an
intronic L1 insertion in the CADPS2 gene is acquired during hiPSC cultivation and disrupts
CADPS2 expression. These experiments elucidate endogenous retrotransposition, and its
potential consequences, in hiPSCs and hESCs.
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H
uman induced pluripotent stem cells (hiPSCs) hold
substantial promise for biomedical applications and as
in vitro models of disease and development. Unlike
human embryonic stem cells (hESCs), hiPSCs are a potential
source of autologous cells compatible with the immune system
of transplant recipients1. hiPSCs also circumvent ethical issues
associated with the use of human embryos1. However, genetic
and epigenetic aberrations that occur during reprogramming
and expansion in vitro2–6 may hinder the use of hiPSCs in
regenerative medicine due to, for instance, an elevated risk of
tumorigenesis upon implantation7. Thus, identifying the full
spectrum of aberrant mutational processes occurring in the hiPSC
genome, and their functional consequences, is of paramount
significance.
LINE-1 (L1) retrotransposons (Fig. 1a) are mobile genetic
elements remaining active in nearly all mammals8. In humans,
500,000 L1 copies contribute 17% of the genome, though only
80–100 L1s per individual remain transposition competent9–11.
L1 mobilization is thought to primarily occur in germ cells
and during early embryonic development and, together with
L1-mediated Alu and SVA retrotransposition, has caused
widespread genome structural variation in human
populations10,12–14. De novo retrotransposition events can
profoundly alter gene structure, expression and function, and
drive pathogenesis15–17. Several intracellular defence mechanisms
have consequently evolved to limit L1 mobility, including histone
modifications and DNA methylation8,18.
Nonetheless, epigenome-wide remodelling19 coincident with
reprogramming appears to enable L1 promoter hypomethylation
and transcriptional activation in hiPSCs20,21. hiPSCs and hESCs
also support low-level retrotransposition of an engineered L1
reporter13,20,22. These observations indicate that the molecular
machinery and substrates required for L1 retrotransposition
exist in pluripotent stem cells. However, genomic analyses of
mouse- and human-derived iPSC populations have to date not
identified endogenous L1 mobilization events23,24. It is therefore
unclear whether endogenous L1-mediated mobilization occurs
during reprogramming or hiPSC cultivation and, as a result, the
potential significance of L1 insertional mutagenesis in hiPSCs
remains unresolved. Here, we describe the dynamics of L1
expression associated with reprogramming, elucidate L1, Alu and
SVA mobilization in hiPSCs, and use an exemplar de novo L1
insertion in CADPS2 to demonstrate the potential impact of
endogenous retrotransposition in pluripotent stem cells.
Results
Dynamic L1 activity in hiPSCs. To elucidate endogenous L1
mobilization associated with hiPSC reprogramming, we first
assembled a panel of eight hiPSC lines and matched parental cells.
Briefly, hiPSCs were derived from human fibroblasts and cord
blood-derived endothelial cells (hCBECs) using several
combinations of reprogramming factors, as well as integrating
and non-integrating delivery systems (Table 1). Extensive
characterization of these lines is described elsewhere25–27 or, as
for hFF-iPS4 and hiPS-SB4, was performed here to confirm
differentiation potential and expression of pluripotency markers
(Supplementary Figs 1 and 2). Noting that genomic aberrations
observed in hiPSCs may occur in small parental cell
subpopulations and only rise to prominence after hiPSC
cultivation28, we ensured that each hiPSC line used in this
study was reprogrammed from a single somatic cell. This lessened
the probability that heterogeneous genomic variants in parental
cells could be erroneously called as de novo in descendant hiPSCs.
As additional controls, we used three hESC lines as benchmarks
of L1 expression and pluripotency (Table 1).
Transcription and translation of functional L1 elements are
prerequisites for L1-mediated retrotransposition. To confirm that
reports of pronounced L1 expression in hiPSCs by Wissing
et al.20 could be extended to the hiPSC lines used in our study, we
measured L1 mRNA abundance, L1 promoter methylation
status and L1 ORF1 protein (ORF1p) expression in fibroblast
(HFF-1)- and hCBEC-derived hiPSCs (hFF-iPS4, hiPS-SB4,
hiPS-SB5, hCBiPS1 and hCBiPS2) and their parental cells
(Table 1; Fig. 1a–d). TaqMan qRT–PCR (quantitative PCR
with reverse transcription) targeting the L1 50UTR (Fig. 1a;
Supplementary Table 1) revealed significantly elevated L1
mRNA levels in each hiPSC line relative to their parental cells
(Po0.05–Po0.0001, analysis of variance (ANOVA)), that peaked
in earlier passages of cell lines hiPS-SB4 and hiPS-SB5
(Fig. 1b)20,21. Northern blot analyses with an L1 50UTR-specific
probe (Fig. 1a) confirmed elevated expression of full-length L1
transcripts in hiPSCs (Fig. 1c). Notably, extended hiPSC culture
led to reduced L1 mRNA abundance (Fig. 1b, left panel;
hiPS-SB4, hiPS-SB5; Po0.05–Po0.001, ANOVA) and
resembled levels observed in hESCs (HES-3, Fig. 1b). Bisulfite
DNA sequencing of the CpG island present in the canonical L1
promoter revealed strong hypomethylation in all tested hiPSC
lines compared to parental cells (P1,2o2 106, Fig. 1d;
P1¼ 2.6 10–12, P2¼ 1.8 10 5, Supplementary Fig. 3; w2
test). Consistently, L1 ORF1p was abundant in hiPSCs, based
on immunoblot (Fig. 1e) and immunofluorescence assays (Fig. 2;
Supplementary Fig. 4). In agreement with previous reports of
cytoplasmic L1 ORF1p expression in human tumours and cancer
cell lines29–31, in hiPSCs, we found L1 ORF1p predominantly
expressed in cytoplasmic foci (Fig. 2b). However, unlike recent
studies focused on other cell types29,32, we did not resolve
whether L1 ORF1p was directed to stress granules in hiPSCs.
Finally, quantitative immunoblot analyses (Supplementary
Methods) revealed a tenfold increase in L1 ORF1p expression
in hiPSCs when compared with parental cells (Supplementary
Fig. 5).
Taken together, our results revealed a spike in L1 expression
during or immediately after reprogramming, confirming previous
findings20,21, followed by attenuation in later hiPSC passages
(Fig. 1b,c). To extend these results, we measured L1 mRNA levels
upon differentiation of late passage hiPSCs (hiPS-SB4 (p98) and
hFF-iPS4 (p50)) into embryoid bodies. We observed 49% and
58% reductions in L1 mRNA levels after 1 and 10 days of
embryoid body differentiation, respectively (Fig. 1b, middle
panel). A parallel assay conducted with early passage hiPSCs
indicated a gradual and significant decrease of L1 mRNA
abundance by up to 65% after 8 days of embryoid body
differentiation and a concomitant increase in differentiation
markers (Fig. 1b, right panel; Supplementary Fig. 6). Hence,
elevated L1 expression in hiPSCs was triggered by
reprogramming and attenuated by short-term cultivation, while,
in turn, subsequent differentiation gradually reduced L1
expression.
Endogenous retrotransposition in pluripotent stem cells. To
unambiguously determine whether activation of the L1 mobili-
zation machinery produced L1-mediated retrotransposition, we
used retrotransposon capture sequencing (RC-seq) to map the
genomic integration sites of de novo retrotransposon insertions.
Briefly, RC-seq involved liquid phase sequence capture to enrich
DNA for the 50 and 30 junctions of recent L1, Alu and SVA
insertions and the surrounding genome33. Putatively immobile
long terminal repeat (LTR) retrotransposons were also probed as
negative controls. Multiplexed, paired-end 150mer Illumina
sequencing of RC-seq libraries, followed by contig assembly,
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Figure 1 | Reprogramming-induced expression of the L1 retrotransposition machinery is abrogated during embryoid body formation. (a) Schematic of
organization and expression of a functional human L1 element. Binding sites of TaqMan primer/probe combinations (small convergent arrows) on L1 cDNA
used for qRT–PCR analyses and of the 1,299-bp [a-32P]dCTP-labelled PCR product in the 50UTR region (black bar) used for northern analysis are shown.
Methylation status of the CpG island (position number 232–491 of the L1.3 reference sequence) was analysed. Open circles, CpG residues. (b) Relative full-
length L1 (FL-L1) mRNA transcript levels were assessed by qRT–PCR from early passage (until p24) HFF-1-derived (hFF-iPS4, hiPS-SB4 and hiPS-SB5) and
hCBEC-derived (hCBiPS1 and hCBiPS1) hiPSC lines (left panel), and after differentiation of hFF-iPS4 (p50) and hiPS-SB4 (p98) lines into embryoid bodies
(EBs) (middle panel) (*Po0.05, **Po0.01, ***Po0.001). hiPS-SB5.1 cells (p10) were differentiated into EBs. L1 transcript levels were quantified on day 0
before initiation of differentiation, and after 2, 4, 6 and 8 days of differentiation by qRT–PCR (right panel; ***Po0.001, linear regression t-test). Bars
represent arithmetic means±s.d. from experiments performed as technical duplicates of biological triplicates, or, in the case of hCBEC, hCBiPS1 and
hCBiPS2 (green bars), arithmetic means of technical duplicates of one biological sample. (c) Northern analysis of cytoplasmic poly-Aþ mRNA with a
1,299-bp L1 50UTR-specific probe confirmed exceeding activation of FL-L1 transcription during hiPSC cultivation. b-Actin mRNA (1.8 kb, lower panel) served
as loading control. (d) Endogenous L1 promoter sequences are significantly hypomethylated in hiPSC lines relative to their parental HFF-1 and hCBEC cells.
Overall percentage methylation of 50UTR CpG islands in HFF-1 and hCBEC cells (n¼ 29 CpG islands; blue bar) and in five derived hiPSC lines (n¼95 CpG
islands; red bar), respectively, is presented. Error bars indicate s.e.m.***Po0.001; w2 test. (e) Immunoblot analysis of cell lysates from HFF-1 and hCBEC
cells and their respective derived hiPSC lines measures L1 ORF1p (40 kDa) and Oct-3/4 expression (A isoform, 45 kDa; B isoform 33 kDa). Shorter (exp.1)
and longer exposures (exp.2) of the aOct-3/4 immunoblot are provided. Lysates from hESC lines HES-3 (left panel) and H1 (right panel) served as positive
control for L1 ORF1p and Oct-3/4 expression. b-Actin (42 kDa) served as loading control.
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provided high-fidelity, single nucleotide resolution of insertions
absent from the reference genome, even at low read depth33.
We analysed all eight hiPSC lines and their matched parental
cells by RC-seq. For five fibroblast-derived hiPSC lines (Table 1),
we included two separate passages each to detect mobilization
events that may have accumulated during cell culture. Similarly,
we analysed two passages each of three hESC lines to evaluate
endogenous retrotransposition during hESC cultivation (Table 1).
Table 1 | Analysed pluripotent stem cell lines and their characteristics.
Stem cell line Parental
cells
Reprogramming
factors
Factor delivery
by
Reference Passages (p)
assayed by
RC-seq
Name Description
hiPS-SB4 HFF-1 Foreskin
fibroblasts (male)
OCT-4, SOX2, KLF4
and c-MYC
Sleeping Beauty
transposon
26 43, 53
hiPS-SB5 OCT-4, SOX2, KLF4,
c-MYC and LIN28
40, 59
hiPS-CRL1502 CRL1502 Dermal fibroblasts
(female)
OCT-4, SOX2,
NANOG, LIN28,
KLF4 and c-MYC
oriP/EBNA1-
based pCEP4
episomal vector
25 15, 40
hiPS-CRL2429 CRL2429 Dermal fibroblasts
(male)
11, 40
hiPS-FB FB Dermal fibroblasts
(female)
OCT-4, SOX2, KLF4
and c-MYC
Lentiviral vector 68 7, 23
hFF-iPS4 HFF-1 Foreskin
fibroblasts (male)
OCT-4, SOX2,
NANOG and LIN28
Unpublished 58
hCBiPS1
hCBiPS2
hCBEC Cord blood-
derived endothelial
cells (male)
OCT-4, SOX2,
NANOG and LIN28
27 30
23
HES-3 hESC lines NA NA 73 92, 102
H9 74 30, 60
HESG Unpublished 10, 23
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Figure 2 | Immunofluorescence staining of hiPSC colonies and their parental cells for endogenous L1 ORF1p expression in HFF-1-derived hiPSCs.
(a) ORF1p staining indicates activation of endogenous L1 expression after reprogramming of HFF-1 cells into lines hiPS-SB4, hiPS-SB5 and hFF-iPS4. Cells
were analysed at passages (p) 23, 16 and 60, respectively. Oct-3/4 staining confirmed the pluripotent status of the analysed stem cell colonies.
Mesenchymal stem cell marker CD105 (endoglin) is reported to be expressed in HFF-1 cells but not expressed in pluripotent stem cells. (b) Enlarged areas
indicated by boxed dashes in a demonstrate cytoplasmic localization of endogenous L1 ORF1p and its accumulation in foci. Scale bars, 20mm.
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RC-seq detected a total number of 40,608 non-reference
retrotransposon insertions including on average 214 L1, 1,411
Alu, 53 SVA and 14 LTR non-reference genome insertions per
hiPSC and hESC sample (Supplementary Fig. 7; Supplementary
Data 1). Insertions were annotated as de novo in pluripotent cells
if they were not (i) reported previously in non-reference
retrotransposon insertion databases9,12,33–38, (ii) found in
parental cells, (iii) found in an earlier hESC passage or
(iv) found in multiple hiPSC or hESC lines. In total, we detected
eight L1, seven Alu and two SVA putative de novo insertions
(Supplementary Data 1). We found no de novo LTR
retrotransposon insertions, despite observing profound
upregulation of HERV-K group HML-2 transcription in hiPSCs
and hESCs (Supplementary Methods; Supplementary Fig. 8).
Five retrotransposon subfamilies (L1-Ta, L1 pre-Ta, AluYb8,
AluYa5 and SVAE) known to be active in humans contributed
putative de novo insertions10,11,39. These were first validated by
genotyping PCR, with seven L1, two Alu and one SVA insertion
confirmed as de novo in hiPSCs and a single Alu insertion (Alu-2)
in hESCs (Fig. 3a; Supplementary Figs 9 and 10; Supplementary
Table 3). The remaining six putative de novo insertions
(one L1, four Alu and one SVA) were detected by PCR in
parental cells or an earlier hESC passage, suggesting that these
variants were present but were not de novo. Next, we determined
the entire nucleotide sequence of 10/11 confirmed de novo
retrotransposon insertions (Supplementary Figs 9 and 10).
For one event, SVA-2, a member of the SVAE subfamily,
we could sequence only the 30 junction, which included a poly-A
tail characteristic of L1-mediated trans mobilization (Fig. 3a;
Supplementary Fig. 9). Our efforts to PCR amplify the matching
50 junction of SVA-2 with multiple primer combinations,
intended to detect a possible 50 SVA truncation or a small
proximal genomic deletion, were unsuccessful (see Methods).
One reasonable explanation for this outcome was the occurrence
of a large 50 genomic deletion at the SVA-2 integration site, as
reported previously13,40–42. Additional sequence analyses
revealed that 9/10 of the remaining insertions exhibited the
canonical hallmarks of L1-mediated target-primed reverse
transcription8,43 including: (i) a target site duplication (TSD),
(ii) a variable length L1 poly-A tail and (iii) an integration site
resembling the L1 endonuclease target motif 50-TTTT/AA-30
(refs 44,45; Fig. 3a; Supplementary Fig. 9). The one exception,
insertion L1-dn4, was 30 truncated within its poly-A signal and
devoid of an L1 endonuclease motif, but nevertheless
incorporated an 8-bp TSD. These features were consistent with
L1 endonuclease-independent retrotransposition46. Insertions
L1-dn6 and L1-dn14 presented one and two untemplated G
nucleotides at their 50 ends, respectively, as seen elsewhere40,42.
Insertions L1-dn3, L1-dn4, L1-dn13 and L1-dn15 exhibited
microcomplementarities of one to five nucleotides at their
50 end, a structural feature reported previously for L1
integration sites47. L1-dn13 and L1-dn15 were also 50 truncated
and inverted, consistent with ‘twin-priming’48, and in one
instance a 50 inversion was displaced from the remaining L1
sequence by a 25-bp DNA fragment of unknown origin
(L1-dn15). Thus, L1-mediated retrotransposition in hiPSCs and
hESCs occurs via mechanisms described previously in
mammalian cells.
The rate of L1-mediated retrotransposition occurring in
pluripotent stem cells was difficult to accurately assess given the
unknown genomic heterogeneity of each population. However, by
estimating the sensitivity of RC-seq, we were able to determine
the approximate L1 mobilization rate in hiPSCs. First, we
identified that the overall RC-seq false positive rate was 1.5%,
based on our recent PCR validation rate of 98.5% for insertions
found by RC-seq in a cohort of hepatocellular carcinoma
patients33 using the same detection thresholds as used here.
Next, we determined that 88.5, 92.8, 88.3 and 89.8% of germline
L1, Alu, SVA and LTR insertions, respectively, found in a parental
cell line or early hESC passage were also detected in the matched
hiPSC or later hESC passage, indicating an overall RC-seq false
negative rate of 7.9%. To then model the sensitivity of RC-seq for
de novo insertions, we randomly sampled each library and
determined the fraction of the total germline events detected in
that library as a function of sampling depth (Supplementary
Fig. 11). At 50% library sampling depth (that is, modelling 50%
variant allele fraction) 71.4%, 76.2%, 68.4% and 87.3%,
respectively, of the germline L1, Alu, SVA and LTR insertions
found in hiPSC lines were detected, dropping to 5.9%, 5.8%, 7.4%
and 27.1% at 5% sampling depth. The estimated overall false
negative rates at 50% and 5% variant allele fraction for de novo
insertions detected in hiPSC lines were therefore 30.5% and
94.4%, respectively. These figures were similar for hESC lines
(31.5 and 94.1%). Thus, we concluded that although RC-seq
reliably detected high variant allele fraction retrotransposon
insertions, a large pool of low variant allele fraction events may
have been overlooked at the RC-seq thresholds used here. This
would be particularly acute in the chosen hESC lines where,
unlike iPSCs, cells had not undergone a recent population
bottleneck in vitro. Using these parameters and the observed de
novo L1 insertion counts, we estimated that hiPSC lines carried
3.7 de novo L1 insertions with allele frequencies Z5%, on
average, extrapolating to B1 de novo L1 insertion per cell
(see Methods). However, the low number of insertions identified
precluded similar estimates for hESC lines.
hiPSC cultivation causes individual L1 copy-number variation.
Our qualitative L1 insertion site validation PCR experiments
(Fig. 3a) indicated that some de novo L1 insertions detected by
Figure 3 | RC-seq reveals endogenous de novo L1, Alu and SVA retrotransposition in pluripotent stem cells. (a) Structures of validated de novo L1,
Alu and SVA retrotransposition events (red box, untranslated region; white box, L1 ORF; green diamonds, TSDs). Names of insertions (for example,
L1-dn10), and gene (for example, SLC12A1) or chromosomal positions for intergenic insertions are listed. RC-seq reads are aligned above the insertions
(red/white bars). Nucleotide positions at 50 ends of L1 and Alu insertions refer to L1.3 and AluYb8 reference sequences, respectively. Corresponding validation
PCRs are presented on the right. a and b, validation primers. (b) Relative L1-dn13 and L1-dn14 copy numbers at hiPS-SB4 passages 43 and 53 were determined
by qPCR. Binding sites of the TaqMan primer/probe combinations specific for the 50 junctions of insertions L1-dn13 or L1-dn14 are shown (Top panels, red
arrows and lines). Genomic DNAs from parental HFF-1 cells, and HES-3 cells served as negative controls. For normalization, a primer/probe combination
specific for the human single-copy gene RPP25 was used. DDCt values measured the relative L1-dn13 and L1-dn14 insertion content, respectively, normalized to
the parental cell line HFF-1. Bars, arithmetic means±s.e.m. of technical triplicates. Due to the minimal s.e.m. observed in the L1-dn14-specific qPCR (right
panel), error bars are not visible. (c) Passaging scheme of the hiPS-SB4 line harbouring L1-dn13. After reprogramming of HFF-1 cells into the hiPS-SB4 line,
hiPSCs were cultivated for 60 passages (culture 1). Genomic DNA (gDNA) was isolated from culture 1 at passages shown in red. Cells of passage 19 were split
and half of the culture was cryo-preserved and cultivated again after several weeks of cryo-preservation (culture 2). gDNA was isolated from passages shown
in blue. (d) Relative L1-dn13 content at passages 43, 56, 58 and 60 of culture 1 (red lettering) and at passages 28, 34, 43 and 49 of culture 2 (blue lettering)
were quantified by qPCR. L1-dn13 is present in passages 43 to 60 of culture 1, but absent from culture 2.
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RC-seq were absent from the earlier hiPSC passage surveyed and
therefore may have arisen after reprogramming. To better
establish the temporal dynamics of L1 retrotransposition in
hiPSCs, we performed multiplex TaqMan qPCR incorporating a
50 junction-spanning probe (Fig. 3b) to quantify L1-dn13 and
L1-dn14 copy-number variation in hiPS-SB4. We observed
an eightfold increase in L1-dn13 copy number upon extended
cultivation (Fig. 3b, left panel) and a Btwo-fold decrease in
L1-dn14 copy number (Fig. 3b, right panel), indicating the
presence of two different hiPS-SB4 subpopulations carrying
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insertions L1-dn13 or L1-dn14, respectively, with opposite
growth dynamics. L1-dn13 and L1-dn14 were not detected in
hESCs (HES-3) or the parental fibroblast (HFF-1) population,
again showing that L1-dn13 and L1-dn14 were de novo
insertions. As the hiPS-SB4 line was cultivated from a single-
cell-derived hiPSC clone, these data showed that either one or
both of these insertions occurred during or after reprogramming,
confirming our RC-seq and genotyping PCR data. To
discriminate whether L1-dn13 arose during hiPSC reprogram-
ming or cultivation, we thawed and extensively cultivated a
passage (p19) of hiPS-SB4 isolated well before the later passages
analysed by RC-seq (p43 and p53) (Fig. 3c). L1-dn13 was not
detected by qPCR in this second hiPS-SB4 cultivar (Fig. 3d).
Hence, L1-dn13 likely arose in the original hiPS-SB4 cultivar
between p19 and p43. We concluded that cultivation of hiPSCs,
and hESCs, as described above for the Alu-2 insertion (Fig. 3a),
can lead to endogenous retrotransposition.
De novo L1 insertions retain retrotransposition competency.
Intriguingly, 4/7 de novo L1 insertions were full length, a
surprising result given that most preexisting genomic L1
retrotransposition events are 50 truncated49. Indeed, only B15%
of L1 copies in the reference genome and o1% of somatic L1
insertions found thus far in tumours are full length33,50,51.
PCR amplification and sequencing of three full-length de novo
L1s (L1-dn4, L1-dn6 and L1-dn14) revealed no deleterious
nonsense mutations in their ORFs (Supplementary Fig. 10),
suggesting each insertion likely retained retrotransposition
competency. As a proof-of-principle, we used an established cell
culture-based L1 retrotransposition reporter assay52 to evaluate
the mobility of L1-dn6 in HeLa cells. L1-dn6 subclones
retrotransposed at a relative efficiency of 20–30% of that
obtained for the benchmark L1.3 (accession no. L19088.1)53
element (Fig. 4) and were therefore classified as highly active or
‘hot’9,11. These data indicated that new, full-length L1 insertions
in hiPSCs could retain substantial competence in initiating
further rounds of mobilization.
L1 insertional mutagenesis disrupts CADPS2 expression. Six
de novo retrotransposition events mapped to introns of
protein-coding genes. These included key factors in neuron
(CADPS2 and NREP) and nephron (SLC12A1) biology, as well as
genes with established and predicted roles in cell cycle regulation
and oncogenesis (PTPN9, RNF38 and PLXDC2). Insertions
showed a marked bias for the 50 end of genes, with insertions
falling on average in the 20th percentile of gene length measured
from the annotated RefSeq transcription start site (TSS), a
significant deviation from random expectation (Po0.006,
permutation test). Albeit based on a small sample of insertions,
this outcome could be explained by L1 endonuclease preference
for open chromatin54 and increased chromatin accessibility
around transcription start sites55.
Given that intronic L1 insertions can disrupt host gene
transcription8,15,56, we noted with interest that all six genes
were expressed in hiPSCs and hESCs57. For example, L1-dn13
occurred in an intron of CADPS2 and, as noted above, exhibited
copy-number variation during hiPSC cultivation (Fig. 3b,d). This
afforded us an opportunity to analyse differential CADPS2
expression with reference to L1-dn13 copy number. First, we
measured and compared CADPS2 mRNA expression in early
versus late hiPS-SB4 passages via TaqMan qRT–PCR (Fig. 5a)
and observed a fivefold reduction in CADPS2 expression in the
latter cells (Fig. 5b). Importantly, this assay tested CADPS2
expression at an exon junction located downstream of the
L1-dn13 integration site (Fig. 5a) and indicated opposing changes
in L1-dn13 copy number (Fig. 3b, left panel) and CADPS2
expression for hiPS-SB4 cells in culture, suggesting that L1-dn13
interfered with CADPS2 expression.
To further test this possibility, we employed a human triose
phosphate isomerase/Renilla luciferase reporter assay developed to
monitor the effects of different introns on mammalian gene
expression58. We generated three constructs (Supplementary
Methods; Supplementary Fig. 12a,b) respectively containing:
(i) 825 bp spanning the empty L1-dn13 target intron of CADPS2
(pSHM06_01), (ii) 423 bp spanning the same region but in this case
containing the 389 bp L1-dn13 insertion and its TSDs to produce a
825 bp sequence (pSHM06_02) and (iii) the 423 bp sequence on its
own (pSHM06_03). We cloned each of these fragments into the
triose phosphate isomerase/Renilla reporter cassette and quantified
their effect on luciferase activity (Supplementary Fig. 12c).
Interestingly, the CADPS2 intron sequence harbouring L1-dn13
(pSHM06_03) had the strongest inhibitory effect and reduced
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Figure 4 | De novo full-length L1 insertions retain retrotransposition
competency in vitro. Intact, full-length L1 insertions L1-dn6-2.2 and L1-dn6-
5.4 were obtained from two independent genomic PCR reactions amplifying
the L1-dn6 de novo insertion, tagged with an mblastI retrotransposition
indicator cassette, and inserted into an episomal expression plasmid where
they were transcriptionally controlled by the CMV promoter. Resulting L1
reporter plasmids pJJ101/L1-dn6-2.2 and pJJ101/L1-dn6-5.4 were submitted
to the L1 retrotransposition reporter assay (see Methods). HeLa cells were
transfected with the L1-dn6 reporter plasmids or with positive and negative
control L1 reporter plasmids pJJ101/L1.3 and pJJ101/L1.3-D702A,
respectively. Blastidicin-S resistant cells arise only if engineered L1
retrotransposition has occurred. pJJ101/L1.3 was used for normalization
(100% activity). pJJ101/L1.3-D702A contains a single point mutation in the
L1 reverse transcriptase domain. The bar diagram depicts arithmetic
mean±s.d. of three independent retrotransposition reporter assays of the
engineered L1-dn6 elements relative to L1.3. Black hexagon, SV40
polyadenylation signal; grey arrows, TSDs flanking a 50-truncated de novo L1
insertion. Blast(s), Blastidicin-S sensitive; Blast(r), Blastidicin-S resistant;
SD, splice donor; SA, splice acceptor.
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Figure 5 | L1-dn13 affects CADPS2 expression. (a) Schematic of the human CADPS2 allele of the hiPS-SB4 line harbouring insertion L1-dn13. A CADPS2
transcript including exons 7, 8, 27 and 28 is presented. Binding sites of the TaqMan primer/probe combination spanning the exon27/exon28 junction on
CADPS2 cDNA used for qRT–PCR analysis are shown (red arrows and line). (b) Relative CADPS2 mRNA levels in early (p16) and late passage
(p50) hiPS-SB4 cells were assessed by qRT–PCR. HES-3 and hFF-iPS4 cells served as positive controls. qRT–PCR results were normalized to 18S rRNA using
CADPS2 expression in parental HFF-1 cells as control. Bars, arithmetic means±s.e.m. of technical triplicates. (c) Structure of the L1-dn13 integration site in
the CADPS2 gene in hiPS-SB4 subclones. hiPS-SB4_D differs from hiPS-SB4_B by the presence of the L1-dn13 de novo insertion in CADPS2 intron 7. Binding
sites of L1-dn13-specific validation PCR primers OP1, ISP1 and ISP2 and expected lengths of the resulting PCR products are indicated. Black diamonds,
TSDs. (d) Genotyping PCR validating the L1-dn13 presence in subclone hiPS-SB4_D and its absence from hiPS-SB4_B in gDNAs isolated from HFF-1,
hiPS_SB4_B, and hiPS_SB4_D cells and from the original mixed population of the hiPS-SB4 culture (hiPS-SB4(Mix)). Primer combinations used are
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confirming absence of L1-dn13 from hiPS-SB4_B and HFF-1 cells, and its presence in hiPS-SB4_D cells and the hiPS-SB4 culture. gDNAs from HFF-1 cells
and from hiPS-SB4(Mix) cells served as negative and positive controls, respectively. For normalization, a primer/probe combination specific for the human
RPP25 gene was used. DDCt values measured the relative quantity of L1-dn13. Bars, arithmetic means±s.e.m. of technical triplicates. (f) Relative CADPS2
mRNA levels in hiPS-SB4_B, hiPS-SB4_D and hiPS-SB4(Mix) cells were determined by qRT–PCR using cytoplasmic RNA and primer/probe combinations
spanning exon 27/exon 28 junction of CADPS2. Bars, arithmetic means±s.e.m. of technical triplicates.
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luciferase activity by 62%, a significant decrease beyond the
constructs lacking L1-dn13 (P¼ 0.022).
As further corollary, we isolated two clones from the original
hiPS-SB4 culture by single cell cloning (see Methods) where
L1-dn13 was identified by RC-seq, one carrying L1-dn13
(hiPS-SB4_D) and the other not carrying L1-dn13
(hiPS-SB4_B) (Fig. 5c). The identity of each clone was verified
by genotyping PCR (Fig. 5d) and qPCR (Fig. 5e). qRT–PCR
applied to cytoplasmic RNA extracted from each clone indicated
that CADPS2 expression wasB95% lower in hiPS-SB4_D than in
hiPS-SB4_B (Fig. 5f). Consistently, CADPS2 expression in the
original hiPS-SB4 culture, which was heterogeneous for the
L1-dn13 allele, was in between expression levels observed for the
hiPS-SB4_D and hiPS-SB4_B clones. We then employed end
point quantitative RT-PCR59 with subsequent capillary
electrophoresis to compare the relative expression of each
CADPS2 allele in hiPS-SB4_D (Supplementary Methods;
Supplementary Fig. 13), as distinguished by a single nucleotide
polymorphism located in the 30UTR of CADPS2. Notably,
L1-dn13 was associated with complete silencing of the CADPS2
mutant allele in hiPS-SB4_D while, interestingly, the CADPS2
wild-type allele was also downregulated by 490% relative to
hiPS-SB4_B. Again, expression of each CADPS2 allele in the
hiPS-SB4 culture heterogeneous for L1-dn13 lay between levels
observed for the hiPS-SB4_B and hiPS-SB4_D subclones.
Altogether, these results conclusively indicate that L1-dn13
interfered with CADPS2 expression.
Discussion
Here we have demonstrated that endogenous L1-mediated
retrotransposition can occur in hiPSCs and hESCs, building
upon earlier reports of engineered L1 retrotransposition in stem
cells13,20,22,60. By contrast, two previous studies reported an
absence of endogenous retrotransposition events in mouse or
human iPSCs23,24. A more recent study reported low-level L1
mobilization in hiPSCs61, though in this case no insertions could
be confirmed by PCR, leaving the validity of the reported putative
L1 insertions unclear. We unequivocally demonstrated here by
RC-seq, gold-standard PCR validation and capillary sequencing,
including L1 integration site structural characterization, that
fibroblast-derived hiPSCs clearly can support the mobilization of
endogenous non-LTR retrotransposons. We speculate that our
use of clonally derived hiPSCs, and the robustness of RC-seq in
detecting somatic L1 insertions33,34, enabled us to discover
retrotransposition events that may have otherwise remained
undetected.
We estimated that hiPSCs each carried B1 de novo L1
insertion, with the notable caveat that this calculation was based
on a small number of observed events. Nonetheless, this is a
much lower rate than recently found for human hippocampal
neurons and glia (13.7 and 6.5 somatic L1 insertions per
cell, respectively)62. Our sensitivity calculations suggested that
most de novo insertions with a variant allele fraction of o5% in
hiPSC and hESC populations were overlooked by RC-seq at the
detection thresholds used here, and these were not included in the
above rate estimate. This is a major consideration in concluding
whether parental cell type or choice of reprogramming vector
affects endogenous retrotransposition activity in hiPSCs. Low
frequency or subclonal retrotransposition may indeed occur in
our hCBEC-derived hiPSC lines, that were reprogrammed via
lentiviral systems, and escaped detection by RC-seq here.
Therefore, we would propose that additional experiments are
required to better define how these and other considerations
(for example, cultivation protocol) affect L1 activity. Indeed, one
explanation for the low number of insertions characterized in
hESCs is that these cell populations were not clonally derived
and were therefore likely to present more extensive genomic
heterogeneity than hiPSCs. The lone Alu insertion found here in
H9 cells is nonetheless the first endogenous retrotransposition
event reported in hESCs, reinforcing evidence that L1-mediated
mobilization can occur in early human development13,63.
L1 activity was highly dynamic during reprogramming and
hiPSC cultivation. Parental cells, early hiPSC passages, later
hiPSC passages and re-differentiated cells presented grossly
different levels of L1 expression. As corroborated by RC-seq,
genotyping PCR and qPCR, the majority of retrotransposition
in hiPSCs likely took place during or immediately after
reprogramming, where we observed a peak in expression of the
L1 mobilization machinery. As a result, each detected variant
could affect substantial hiPSC subpopulations. Interestingly,
major induction of L1 mRNA and protein expression, far in
excess of that seen in hESCs and neural stem cells13,60, was
accompanied by a comparatively modest increase in L1
mobilization rate. Due to drastic epigenetic changes occurring
upon reprogramming, it is possible that reprogramming per se
may activate the expression of cellular L1 restriction factors such
as APOBEC proteins22 and PIWIL2 (ref. 64). Consistently,
APOBEC3B and PIWIL2 have been demonstrated to control
engineered L1 retrotransposition in hiPSCs22,64. Thus, it is
tempting to speculate that the cellular milieu of hiPSCs and
hESCs may permit L1 upregulation but also limit L1-mediated
mutagenesis.
That 4/7 of the de novo L1 insertions reported here were
full-length was consistent with 2/3 of the engineered L1 de novo
insertions characterized by Wissing et al. also being full-length20.
This 450% incidence of full-length L1 de novo insertions in
hiPSCs is unexpected as only B15% of L1 copies in the human
reference genome ando1% of somatic L1 insertions identified in
tumours are full length33,36,50,51. However, 7/7 engineered L1
retrotransposition events found in hESCs were recently reported
to be significantly 50 truncated13, suggesting that pluripotency
factors common to hiPSCs and hESCs might not play any role in
the observed overrepresentation of full-length de novo L1
insertions found in hiPSCs. The mechanism of L1 50 truncation
is not fully understood. On one hand, the preponderance of 50
truncated L1 copies in the genome has long been explained by an
inability of the L1 reverse transcriptase encoded by L1 ORF2p to
copy the entire template L1 RNA, either due to premature
dissociation of the L1 reverse transcriptase from its RNA or
competition from an unknown cellular RNase that digests the L1
RNA before completion of reverse transcription65. Therefore, it is
possible that hiPSCs provide a nuclear environment allowing a
more stable association of the L1 reverse transcriptase with L1
RNA, or the L1 reverse transcriptase does not have to compete
with a cellular RNAse which might be differentially expressed in
hiPSCs. On the other hand, a recent study demonstrated that the
DNA-damage-signalling protein ATM may control the length or
number of de novo L1 insertions in human neural stem cells66.
Thus, it is possible that subtle differences in the DNA repair
mechanisms operating in hiPSCs and hESCs could be related to
the high frequency of full-length L1 insertions characterized in
hiPSCs.
Each de novo L1 insertion reported here integrated in a
protein-coding gene expressed in pluripotent cells. In one case,
we identified an L1 insertion (L1-dn13) that arose during hiPSC
cultivation and integrated into an intron of the gene CADPS2.
It remains to be determined whether acquisition of L1-dn13, and
a concurrent reduction in CADPS2 expression, imbued carrier
hiPSCs with a selective advantage in vitro. Furthermore, it
remains unclear why transcription of the CADPS2 allele lacking
L1-dn13 was reduced by 490%. To speculate, it is possible that
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CADPS2 expression involves a direct or indirect positive feedback
loop where, for example, transcription from CADPS2 reinforces
open chromatin67. A reduction in CADPS2 expression caused by
L1-dn13 could hence have a strongly negative effect on
transcription from the wild-type CADPS2 allele.
In closing, it is notable that intronic L1, Alu and SVA
insertions can alter cellular phenotype and are associated
with numerous instances of human disease56. Future in-depth
experiments are however required to definitively establish
whether endogenous retrotransposition alters the phenotype of
hiPSC derivatives sufficiently to impact their use in medical or
research applications. We can nevertheless conclude that
retrotransposition, in addition to other sources of genetic and
epigenetic variation2–6, can change the functional landscape of
the hiPSC genome.
Methods
Cell lines and culture conditions. hiPSC lines hiPS-SB4 (hFF-T2-OSKM) and
hiPS-SB5 (hFF-T2-OSKML)/hiPS-SB5.1 (hiPS-OSKML#6) were generated by
reprogramming HFF-1 cells (ATCC-Number: SCRC-1041) using Sleeping Beauty
(SB) transposon-based plasmids pT2-OSKM or pT2-OSKML which contain
polycistronic OSKM (OCT4, SOX2, KLF4 and c-myc) or OSKML (OSKMþ LIN28)
expression cassettes26. Briefly, HFF-1 cells (4 105 cells per well) were transfected
by nucleofection (Lonza) according to the manufacturer’s instructions. In each
transfection, 2 mg of transposon plasmid (pT2-OSKM or pT2-OSKML) and 0.2 mg
of CMV- SB100X vector (harbouring the enhanced Sleeping Beauty transposase
gene under control of a CMV promoter26) were used. After transfection cells were
plated onto Matrigel-coated six-well plates (hESC-qualified Matrix, BD
Biosciences) and were grown in MEF-conditioned ESC medium used for the
cultivation of hESCs and hiPSCs. ESC medium consisted of Knockout DMEM
(Life Technologies) supplemented with 4 ngml 1 basic fibroblast growth factor 2
(FGF2, Invitrogen), 20% Knockout Serum Replacement (Gibco), 1mM L-glutamine
(Biochrom AG), 50 mM b-mercaptoethanol and 0.1mM nonessential amino acids.
The medium was replaced every day. Newly formed hiPSC colonies were picked,
transferred to Matrigel-coated 24-well plates, and expanded for 4–6 days in
MEF-conditioned ESC medium. Subsequently, cells were trypsin dissociated, plated
onto feeder cells and cultivated in ESC medium.
In this experiment, cells nucleofected with SB-OSKM gave rise to only one
hiPSC colony. Nucleofection with SB-OSKML resulted in several hiPSC colonies.
Multiple SB-OSKML colonies were picked and transferred onto the same
Matrigel-coated wells. After establishing a mixed culture of hiPSCs generated with
either SB-OSKM or SB-OSKML, single-cell-derived hiPSC clones were generated
by single-cell dilution using cell sorting (see below) based on their positivity for
SSEA4. Six SB-OSKML hiPSC clones and one SB-OSKM hiPSC clone were then
characterized for pluripotency and differentiation potential as described26. Two
SB-OSKM hiPSC clones (hiPS-SB5 and hiPS-SB5.1) and the only SB-OSKM hiPSC
clone (hiPS-SB4) obtained were used in this study.
The lines hiPS-CRL1502 (ref. 25), hiPS-CRL2429 (ref. 25), hCBiPS1 (ref. 27),
hCBiPS2 (ref. 27) and hiPS-FB68 have been described previously. hFF-iPS4 was
produced using HFF-1 cells and a lentiviral vector expressing reprogramming
factors Oct-4, Sox2, Nanog and Lin28 (ref. 27). Successful reprogramming for the
hFF-iPS4 cell line was verified by morphology, pluripotency marker expression
(Supplementary Fig. 2), karyotype analysis and the ability to generate teratomas on
immunocompromised mice.
hESC lines H1, H9 and HES-3 were purchased from the WiCell Research
Institute (Madison, WI, USA) and Cythera Inc. (San Diego, CA, USA). The H1 line
was used exclusively for the isolation of cell lysate that was loaded as positive
control of the immunoblot analysis in Fig. 1e, right panel. hESC line HESG
(GENEA23) was purchased from GENEA Biocells (http://www.geneastemcells.
com.au). It formed well-defined colonies with compact cells displaying a high
nuclear to cytoplasmic ratio and prominent nucleoli. Karyotype analysis (46
chromosomes, XY male) did not uncover any abnormalities at passage 42. HESG
cells express pluripotency markers Nanog, Oct-4, Tra1-60 and SSEA4, stain
positive for alkaline phosphatase and form teratomas. As for hiPSCs, hESCs were
grown on gelatin-coated six-well plates (Greiner) on inactivated mouse embryonic
fibroblasts (MEFs, passage 3, strain CF1; Merck Millipore, Catalogue Number:
PMEF-CFL). MEFs were expanded and mitotically inactivated by g-irradiation
with a Cesium source with 30Gy after 3–7 passages, and stored in liquid nitrogen
until further use. After thawing, MEFs were seeded at a density of 6 105 cells per
well of a six-well plate. hESC medium was replaced daily and cells were passaged at
a 1:2 dilution every 5 days using splitting medium (1mgml 1 collagenase IV
(Gibco, Darmstadt, Germany) in KO-DMEM).
Cell sorting. hiPSCs were washed once in PBS containing 0.5% bovine serum
albumin, and incubated for 30min with allophycocyanin-conjugated anti-human
SSEA4 antibody (R&D Systems). In all samples an anti-mouse Sca-1 (Ly-6A/E)
(FITC or PE conjugated, BD Pharmingen) antibody was employed, for gating out
the positively labelled mouse feeder cells. Samples were analysed and sorted using
an Aria High Speed Cell Sorter (Becton-Dickinson).
Differentiation of hiPSCs into embryoid bodies and RNA extraction. In all
experiments, hiPSCs grown on MEFs were detached from the feeder layer by
adding 250 ml Collagenase Type IV (1mgml 1; Gibco) per well of a six-well tissue
culture plate. Next, cells were resuspended in 750ml of ESC medium, transferred to
a 15ml conical tube and centrifuged at 800 r.p.m. in a Heraeus Multifuge 4KR for
3min at room temperature. Subsequently, medium was removed, cells were
resuspended in 3ml of ESC medium without FGF2 and cultured for 1–16 days in
T25 flasks (Greiner) containing 10ml of ESC medium without FGF2. At the
indicated time, embryoid bodies were harvested and cytoplasmic RNA was isolated
as described below. Passage 10 of the hiPSC line hiPS-SB5.1 was cultured in one
well of a GeltrexTM-coated six-well culture dish, and treated with collagenase IV
(1mgml 1) for 5min. Cells were washed with warm PBS twice, and fed with 1ml
embryoid body formation medium (Knockout DMEM, 20% Knockout Serum
Replacement, 1mM L-Glutamine, 1% nonessential amino acids, 0.1mM
b-mercaptoethanol and Primocin (Invivogen)) and split into small cell clumps.
hiPSC colonies were then dissociated with collagenase IV (1mgml 1) for 5min,
and split into small cell clumps. Cell clumps were transferred into three 10-cm
low-attachment dishes and fed with embryoid body medium. The medium was
changed every 2 days. Embryoid bodies were cultured for 8 days in total. Embryoid
bodies were collected by sedimentation under gravity from three dishes on day 0
(undifferentiated hiPSCs), 2, 4, 6 and 8, respectively (Fig. 1b, right panel;
Supplementary Fig. 6). Total RNA was extracted from each well using Trizol
(Invitrogen) following the instructions of the manufacturer.
Analysis of expression in embryoid bodies by qRT–PCR. To analyse the
expression of both pluripotency markers and L1, real-time quantitative RT–PCR
was applied. To this end, 0.1 mg total RNA per well was used for reverse
transcription by using the High Capacity RNA-to-cDNA kit (Applied Biosystems).
For each time point and transcript to be quantified, qRT–PCR analyses were done
in triplicate. qRT–PCR for pluripotency/differentiation markers was carried out
using Power SYBR Green PCR Master Mix (Applied Biosystems) on the
ABI7900HT sequence detector (Applied Biosystems), and data was normalized to
GAPDH expression. qRT–PCR for L1 was performed with ABsolute QPCR Mix
(ABgene), and data was normalized to 18S rRNA expression.
qRT–PCR using TaqMan fluorogenic probes. Cytoplasmic RNA was extracted
from 5 106 to 3 107 somatic cells, hiPSCs or embryoid body cells using the
RNeasy Midi Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Cytoplasmic RNA (0.5–1 mg) was incubated with 2U of RNAse-free
DNaseI (Life Technologies, Darmstadt, Germany) for 30min at room temperature.
DNAseI digestion was stopped by adding 2 ml of 25mM EDTA and incubation for
10min at 65 C. DNAseI-digested cytoplasmic RNA (0.1–0.5 mg) was used for
cDNA synthesis using the SuperScript III First-Strand Synthesis Kit (Invitrogen) in
combination with a Random Hexamer Primer (0.5 mg ml 1; Invitrogen) according
to the manufacturer’s instructions. Quantitative real-time PCR was carried out in
ABgene plates using an Applied Biosystems 7900HT Fast Real-Time PCR System.
The primer and probe combination L1 50UTR#2 (ref. 60) was used to quantify
transcripts expressed from endogenous L1-Ta copies. Sequences of
oligonucleotides and probes used for qRT–PCR are listed in Supplementary
Table 1. The probe specific for the L1 5’UTR was labelled with the reporter
fluorochrome 6-carboxy-fluorescein (FAM) and a non-fluorescent quencher. 18S
rRNA expression was quantified using Eukaryotic 18S rRNA endogenous control
(VIC/TAMRA Probe, Primer Limited; Part number 4310893E, Applied Biosys-
tems). Transcript levels of the human CADPS2 gene were monitored using a gene
specific assay (Life Technologies, Hs00604528_m1) spanning exon sequences
(Fig. 5a). Cycling conditions were the following: 95 C for 15min (one cycle), 95 C
for 15 s and 60 C for 1min (40 cycles). A total of 1–5 ml of cDNA per sample were
used for the quantification of endogenous L1 and CADPS2 mRNA levels. Analysis
of real-time and end point fluorescence was performed using the software SDS
version 2.3 as well as RQ manager 1.2 (Applied Biosystems).
Northern blot analysis. Total RNA was isolated from the cell lines HFF-1, 2102Ep
(ref. 69), HES-3 and hiPS-SB4 using TRIzol (Invitrogen) according to the
manufacturer’s instructions. Poly(A)þ RNA was isolated applying the Dynabeads
mRNA Purification Kit (Life Technologies) according to the manufacturer’s
instructions. Denatured mRNA (2.8 mg) from each cell line was subjected to
denaturing electrophoresis in a horizontal 1% agarose gel containing
morpholinepropanesulfonic acid buffer and 6% formaldehyde, and transferred
onto a Hybond-Nþ -Nylon membrane (Amersham) by overnight capillary transfer
using 10 SSC as transfer buffer. A total of 4 ml RiboRuler High Range RNA
ladder (MBI Fermentas, St.Leon-Rot, Germany) were loaded as size marker. After
crosslinking the RNA onto the membrane by ‘baking’ at 80 C for 2 h, the
membrane was prehybridized overnight in 50% Formamide/4xSSC/1%SDS/2
Denhardt’s at 42 C. The full-length L1 mRNA-specific probe was generated by
PCR amplification of a 1299-bp L1 fragment ranging from position numbers (pos.)
58–1356 of a full-length L1 element by using primers L1_FW1 and L1_RV1
(Supplementary Table 1) and pJM101/L1RPDCMV70 as template. Pos. refer to the
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L1.3 element53 sequence (accession number L19088.1). A 491-bp b-actin
mRNA-specific probe was generated by PCR amplification using primers actin_FW
and actin_RV_(Supplementary Table 1) and plasmid 31502 (Addgene71) as
template. PCR fragments were labelled with [a-32P]dCTP by applying the Nick
Translation System (Invitrogen) according to the manufacturer’s instructions.
After denaturing the probe for 10min in boiling water and subsequent
incubation for 10min in ice water, the probe was added to the hybridization buffer
(50% Formamide/4 SSC/1% SDS/1 Denhardt’s) and the membrane was
incubated in the probe-containing hybridization buffer overnight at 42 C.
Subsequently, the membrane was subjected to two 5min low-stringency washes
(2 SSC) at room temperature and one 30min high-stringency wash (2
SSC/0.5%SDS) at 65 C. The membrane was stripped by being boiled for 30min in
a solution of 10mM tris-HCl (pH 7.5)/1mM EDTA/1mM SDS. The hybridized
membrane was exposed to X-ray films for 5–10 days with intensifying screens.
Bisulfite DNA sequencing analyses. Bisulfite DNA sequencing analyses were
performed as previously described20,60. Briefly, genomic DNA from hiPSCs and
parental cells was isolated at the indicated passage using DNAzol Genomic DNA
Isolation Reagent (MRC Inc, Cincinnati, OH, USA) according to the
manufacturer’s instructions. Next, 2 mg of genomic DNA were bisulfite converted
using an EpiTect Bisulfite Kit (Qiagen, Hilden, Germany) following manufacturer
instructions, with a conversion efficiency of B95%. To determine the DNA
methylation status of L1-Ta promoters, we performed PCR sequencing using
primers L1-FW2: 50-AAGGGGTTAGGGAGTTTTTTT and L1-RV2: 50-TATC
TATACCCTACCCCCAAAA. To this end, 300–500 ng of converted genomic DNA
were used in a 50ml PCR reaction as follows: 2min at 95 C, 35 cycles of 30 s at
94 C followed by 30 s at 54 C and 60 s at 72 C, and a final extension of 10min at
72 C. Amplified products were gel purified (QIAquick gel extraction kit, Qiagen),
cloned in pGEM-T Easy (Promega) and at least 30 individual clones were
sequenced for each sample. The unique sequence in each clone was analysed using
Repeatmasker at http://www.repeatmasker.org/cgi-bin/WEBRepeatMasker. Next,
the fraction of unmethylated CpG sites was calculated by comparison to a
consensus L1-Ta sequence. In addition, each individual sequence was compared to
L1.3 and only the sequences with the highest homology to this sequence were used
to plot methylation data in single clones (Supplementary Fig. 3d). The proportion
of CpG converted to TpG by bisulfite treatment was compared between samples
using the w2 test (d.f.¼ 1; a¼ 0.05).
Immunoblot analysis. hiPSC colonies were detached from their tissue culture dish
by incubation with 250ml of a 1mgml 1 collagenase type IV/DMEM and washed
subsequently in 1 PBS. Cells were spun down, resuspended in lysis buffer
(50mM Tris-HCl (pH 7.4), 150mM NaCl, 10% Glycerin, 1% Triton X-100; 2mM
EDTA, 2mM EGTA, 40mM b-Glycerolphosphate disodium salt hydrate, 50mM
NaF, 10mM Na4P2O7, 200 mM Na3VO4, 2mM DTT; 1 complete protease
inhibitor cocktail (Roche Applied Science)), homogenized by passing the lysate ten
times through a 26G needle, and lysates were cleared by centrifugation. A total of
50mg of each protein lysate were boiled in 3 SDS sample buffer (NEB),
loaded on 4–12% Bis/Tris gels (Invitrogen), subjected to SDS–polyacrylamide gel
electrophoresis, and electroblotted onto nitrocellulose membranes. After protein
transfer, membranes were blocked for 2 h at room temperature in a 10% solution of
non-fat milk powder in 1 PBS-T (137mM NaCl, 3mM KCl, 16.5mM Na2HPO4,
1.5mM KH2PO4, 0.05% Tween 20 (Sigma-Aldrich Chemie GmbH, Mannheim,
Germany)), washed in 1 PBS-T, and incubated overnight with the respective
primary antibody at 4 C.
L1 ORF1p and Oct-4 proteins were detected using the polyclonal rabbit-anti-L1
ORF1p antibody #984 (ref. 41) at a 1:2,000 dilution and the Oct-3/4 (C10) antibody
(sc-5279, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) at a 1:750 dilution,
respectively, in 1 PBS-T containing 5% milk powder as primary antibodies.
Subsequently, membranes were washed thrice in 1 PBS-T. As secondary
antibodies, we used HRP-conjugated donkey anti-rabbit IgG antibody at a 1:30,000
dilution to detect L1 ORF1p, and HRP-conjugated donkey anti-mouse IgG
antibody at a 1:10,000 dilution (Amersham Biosciences) to detect Oct-3/4, in
1 PBS/5% milk powder and incubated the membrane for 2 h. Subsequently, the
membrane was washed thrice for 10min in 1 PBS-T. b-Actin expression was
detected using a monoclonal anti-b-actin antibody (clone AC-74, Sigma-Aldrich
Chemie GmbH, Steinheim, Germany) at a dilution of 1:30,000 as primary antibody
and an anti-mouse HRP-linked species-specific antibody (from sheep) at a dilution
of 1:10,000 as secondary antibody. Immunocomplexes were visualized using
lumino-based ECL immunoblot reagent (Amersham Biosciences Europe GmbH,
Freiburg, Germany). Details of the applied antibodies are listed in Supplementary
Table 2. Full scans of immunoblots are presented in Supplementary Fig. 14.
Immunofluorescence staining. hiPSCs as well as their parental HFF-1 or hCBEC
cells were grown on glass cover slips in 12-well plates. Cells were washed with
1 PBS, fixed with 4% paraformaldehyde in 1 PBS (pH 7.4) for 15min at room
temperature and permeabilized with 1% Triton X-100 (Sigma) in 1 PBS for
10min at room temperature. Subsequently, cells were washed thrice for 2min
in 1 PBS. Cells were blocked by incubation with 5% (w/v) BSA/0,1% Triton
X-100/1 PBS (pH 7.4) for 30min at room temperature followed by incubation
with the respective primary antibodies, which are listed in Supplementary Table 2,
for 1 h at room temperature in 5% BSA/1 PBS (pH 7.4). Subsequently, cells were
washed three times with 1 PBS for 5min each at room temperature. Cells were
incubated with the appropriate secondary antibody: goat-anti-mouse IgG Alexa
488 or goat-anti-rabbit IgG Alexa 643 (Invitrogen) at 1:1,000 dilution in 5%
BSA/1 PBS (pH 7.4) for 30min at room temperature in the dark. Finally,
preparations were washed thrice for 5min each at room temperature using
1 PBS. Subsequently, cells were counterstained with DAPI (4,6-diamidino-2-
phenylindole; Sigma-Aldrich), washed thrice with 1 PBS for 10min at room
temperature, embedded in Fluoromount G (Southern Biotech) and kept at 4 C
until further analysis. The analysis was performed using an Axio Observer A1
microscope (Carl Zeiss MicroImaging, Goettingen, Germany).
RC-seq library preparation, sequencing and analysis. Genomic DNA was
isolated from 1 106 cells from each hESC and hiPSC line and their respective
parental cells using DNAzol Genomic DNA Isolation Reagent (MRC Inc,
Cincinnati, OH, USA) according to the manufacturer’s instructions. RC-seq and
subsequent computational analyses were performed as described using the hg19
reference genome sequence33. A total of 665,008,770 2 150mer reads were
generated from 24 libraries. A complete list of annotated de novo insertions
supported by at least two unique amplicons separated by Z5 nt (the minimum
threshold for reporting) is provided in Supplementary Data 1. To assess the RC-seq
false negative rate, we randomly sampled each library in increments of 1% (10
samplings per percentile) and determined how many germline insertions were
detected at the sampled depth by Z2 unique reads (Supplementary Fig. 11). To
approximately assess the rate of L1 mobilization in hiPSCs, we again randomly
sampled each RC-seq library to determine the probability of detecting each de novo
L1 insertion with Z2 unique reads at a given sampling depth, normalized to the
corresponding false negative rate identified above and then determined the
cumulative sum of this distribution for frequencies of 5–100%, leading to an
estimate of B1 de novo L1 insertion per hiPSC. We did not consider de novo L1
insertions carried by fewer than 5% of hiPSCs in this estimate as none of the
validated examples were routinely identified at that sampling depth. We also did
not analyse the L1 mobilization rate in hESCs or the Alu or SVA rate in hiPSCs or
hESCs due to the small number of confirmed true positive examples.
A permutation test showing enrichment for validated de novo L1 insertions at
the 50 end of genes was performed by random sampling of genomic coordinates,
with respect to RefSeq annotations. 1 106 permutations were performed and in
6,000 instances the average position was less than the 20th percentile of gene
length, indicating Po0.006.
PCR validation of de novo insertions. Seventeen de novo insertions (eight L1,
seven Alu and two SVA) detected by RC-seq were first assayed with PCR using a
standard empty site/filled site genotyping assay. Primers were positioned on either
side of the insertion site so that the predicted PCR product of the empty site
covered o300 bp. Additional retrotransposon specific primers were designed and
paired with the existing insertion site-specific primers if required. In cases where an
insertion was detected by RC-seq at one terminus only, PCR and capillary
sequencing were applied to the remaining end to resolve integration site structure.
PCR reactions contained 0.125 ml Crimson Taq (New England Biolabs), 5
PCR-buffer, 10pMol of each Primer, 10mM dNTPs and 10–20 ng genomic
template DNA in a total volume of 25 ml. The following cycling conditions were
used: 95 C for 2min, then 35 cycles of 95 C for 30 s, 58 C for 30 s, 68 C for 40 s,
followed by a single extension step at 68 C for 5min. Optimization in some cases
required adjusted annealing temperatures and cycle number. PCR products of the
correct size (Fig. 3a) that were obtained with the retrotransposon primer in
combination with the genomic primer were TA-cloned and sequenced. The same
method was applied to both the 50 and the 30 ends of all de novo insertions to fully
characterize each, apart from SVA-2. To PCR amplify the 5’ junction of the SVA-2
insertion from genomic DNA, we designed three SVAE-specific primers and three
oligonucleotides binding 50–300 bp upstream of the SVA-2 integration site. To
facilitate the detection of a potentially 50-truncated SVA, the SVA-specific primers
were placed within the sequenced 123 bp of the SVA-2 30 end (Supplementary
Fig. 9), at the junctions of the SVAE-specific Alu-like and VNTR region, and the
(CCCTCT)n repeat and Alu-like region, respectively. Combinatorial use of these
genome-SVA primer pairs did either not result in a PCR product or generated
non-specific products. For a complete list of used primers see Supplementary
Table 3. Eleven de novo insertions (seven L1, three Alu and one SVA) were
confirmed by PCR as de novo. Six additional insertions were determined as
germline insertions, already present in the parental cell line or an early hESC
passage. Control genotyping PCR of the single-copy gene GAPDH in genomic
DNA preparations of parental and hiPSC lines used for RC-seq and PCR
validations of de novo insertions is presented in Supplementary Fig. 15. PCR
amplification was performed using primers GAPDH-a (50-CAAAGCTTGTGC
CCAGACTGTG30) and GAPDH-b (50-GAGAGCTGGGGAATGGGACT30)
which bind in exon 8 (chr12:6646561-6646580) and intron 7 (chr12:6647005-
6647026), respectively, resulting in a 466-bp DNA fragment. Cycling conditions
were identical to those described above.
Quantification of L1-dn13 and L1-dn14 copy numbers by qPCR. To determine
relative copy numbers of de novo insertions L1-dn13 and L1-dn14 within the
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hiPS-SB4 culture, we applied real-time qPCR using TaqMan fluorogenic probes. To
this end, genomic DNA was isolated using 1ml DNAzol Genomic DNA Isolation
Reagent (MRC Inc, Cincinnati, OH, USA) from 1 106 cells, according to the
manufacturer’s instructions. A total of 100 ng of genomic DNA was used for
quantitative real-time PCR (qPCR). Primer and probe combinations specific to the
genomic 50 junctions of the de novo insertions L1-dn13 and L1-dn14 (Fig. 3b)
were used to quantify the copy number of the respective insertion in hiPSC cul-
tivars. Each probe was labelled with flourochrom6-carboxyfluorescein and a
non-fluorescent quencher. For normalization the single-copy gene RPP25
(Ribonuclease P/MRP 25kDa subunit; FAM/non-fluorescent quencher, primer
limited, HS00706565_S1; Applied Biosystems) was used. Cycling conditions were:
95 C for 15min (one cycle), 95 C for 15 s and 60 C for 1min (40 cycles). For
analysis of real-time and end point fluorescence, the software SDS version 2.3 as
well as RQ manager 1.2 (Applied Biosystems) were used.
Isolation of hiPS-SB4 single-cell subclones. To isolate single cell subclones from
the hiPS-SB4 culture by limiting dilution, hiPS-SB4 cells of passage 64
representing a mixed population of cells with and without the L1-dn13 de novo
retrotransposition event, were magnetically separated from feeder cells by applying
a Feeder Removal Kit (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions. hiPSCs were counted and seeded on
feeder-coated 96-well plates (Catalogue no.: 167008, Thermo Fisher/Nunc, Ros-
kilde, Denmark) at a cell density of one cell per well or 0.3 cells per well. hiPSCs
were grown for 24 h in the presence of 10 mM ROCK inhibitor (Y-27632, Sigma-
Aldrich). Subsequently, cells were cultivated until they formed a single colony per
well. Single colonies were transferred to feeder-coated 12-well plates (Thermo
Fisher/Nunc) and further expanded. To isolate genomic DNA from each clone,
cells were harvested after collagenase IV treatment, centrifuged, washed and pel-
leted again. Genomic DNA was isolated as described in the previous paragraph.
Genotyping PCR conditions applied to screen for the presence of the L1-dn13
insertion and to demonstrate its presence/absence (Fig. 5d) are identical to
those described above for insertion PCR validation. Primers used to demonstrate
presence/absence of L1-dn13 are provided in Supplementary Data 1 and
Supplementary Table 3. PCR products were visualized on a 1.5% agarose gel after
ethidium bromide staining.
L1 retrotransposition reporter assays. De novo full-length L1 insertions were
amplified from genomic DNA using an Expand Long Template PCR system
(Roche) and primers located 50 bp upstream/downstream the insertion site
(available upon request). For each PCR we used: 0.3 ml Expand Long Template Taq
(Roche), 1 buffer#1, 400 mM dNTPs, 1 mM each Primer and 300 ng genomic
DNA in 50ml per tube. Cycling conditions were: 95 C for 5min, then 30 cycles of
95 C for 1min, 56 C for 30 s, 68 C for 6min, followed by a single extension step
at 68 C for 10min. To avoid the generation of mutations that may lead to ret-
rotransposition defective elements, we conducted at least four independent PCRs
per L1. PCR products were resolved on 0.9% agarose gels, and fragments of the
expected length of B6 kb representing potential full-length L1 elements were
excised and purified using a Qiaquick kit (Qiagen) and cloned in the Topo-XL
plasmid (Invitrogen). Each of the cloned PCR products carrying full-length L1
elements L1-dn4, L1-dn6 and L1-dn14 were sequenced (Supplementary Fig. 10).
To evaluate retrotransposition competence of the L1-dn6 de novo insertion, two
independent genomic PCR amplicons, L1-dn6-5.4 and L1-dn6-2.2, were sequenced
and inserted into the pJJ101/L1.3 backbone after the deletion of its L1.3 sequence
by Not I/BstZ17I restriction9,72. pJJ101/L1.3 contains the active full-length L1.3
element tagged with an mblastI retrotransposition indicator cassette72 cloned in
vector pCEP4 (Invitrogen). In total, we generated five JJ101-derived plasmids
containing an L1-dn6 element amplified from genomic DNA by PCR. For
retrotransposition assays, these L1 reporter plasmids were purified using a Qiagen
Midiprep system (Qiagen) and only highly supercoiled preparations were used in
the following assays.
Retrotransposition assays in HeLa cells were conducted as described
previously9,46,52,72. HeLa cells were purchased from ATCC. Cytogenetic
authentication of HeLa cells was performed by spectral karyotyping (SKY)-FISH.
HeLa cells used in this study were tested for mycoplasma contamination monthly.
Briefly, HeLa cells were cultured using DMEM-high glucose (4.5 g l 1)
supplemented with L-glutamine, Penicillin/Streptomycin, and 10% fetal bovine
serum (all reagents from GIBCO-Invitrogen) and passaged using Trypsin 0.05%
(GIBCO-Invitrogen). 104 HeLa cells per well were plated in triplicate using six-well
tissue culture plates. After 18 h, cells were transfected with 1 mg per well of
plasmid using 3 ml of Fugene6 (Promega) following manufacturer’s instructions.
Next day, medium was replaced and cells cultured for five additional days.
Six days after transfection, Blasticidin-S (Invitrogen) was added to a final
concentration of 10 mgml 1 and cells were cultured for seven days in the presence
of the antibiotic. Next, plates were fixed and stained with crystal violet, and foci
counted manually.
Statistical analyses of relative L1 RNA levels. The statistical evaluation of
relative L1 mRNA levels determined by qRT–PCR was performed by ANOVA,
using Bonferroni correction for multiple comparisons with the same control group.
Reduction in full-length transcript levels in the embryoid body time kinetics
experiment was evaluated by means of Linear Regression for data from day 0 to day
8 (R2¼ 0.79). Analyses were performed with SAS/STAT software, version 9.2 SAS
system for Windows.
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